Global top pharmaceutical companies by oncology market share 2017 and 2024

Swiss -based company Roche was the global leader based on oncology market share in 2017 and is forecasted to maintain this position until 2024. However, it is expected that the market share will decrease dramatically from the current 26 percent to under 12 percent by 2024. The main reason for this development is that competitors like Celgene, Bristol Myers-Squibb, and Johnson and Johnson will dominate with their key oncology products by that year. Additionally, several of Roche’s blockbuster oncologic drugs will face sales erosion due to biosimilar competition.

Oncology market overview

The oncology market is expected to increase with a compound annual growth rate of twelve percent worldwide between 2017 and 2024. Traditionally, oncology is one of the three leading therapy classes worldwide by spending, accompanied by pain medication and antidiabetics. Around 45 percent of the global market is generated in the United States alone, making it the world’s top national oncology market. Another 20 percent of the market remains in the leading five EU- countries. At this moment, the three best-selling cancer drugs worldwide are Celgene’s Revlimid and Roche’s Rituxan and Herceptin.

The rise of immune-oncology

The aim in immunotherapy is the same as with immunizations (vaccinations) – to use the human body’s inherent defenses to fight the disease. Immune-oncology is a type of immunotherapy that specifically targets cancer cells. The great advantage of immune-oncology is the targeted approach, which leaves the rest of the body unharmed compared to traditional treatments. The fight against the many types of cancer is still one of the great challenges in modern medicine and personalized treatments already show huge potential. The global cancer immunotherapy market is projected to reach 117 billion U.S. dollars by 2022.

Top 10 pharmaceutical companies based on global oncology market share in 2017 and 2024

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

June 2018



Survey time period

as of May 2018

Supplementary notes

* Projections.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Oncology"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.